Literature DB >> 33586982

99mTc-CN7DG: A Highly Expected SPECT Imaging Agent of Cancer with Satisfactory Tumor Uptake and Tumor-to-Nontarget Ratios.

Qianqian Gan1, Xuran Zhang1, Qing Ruan1, Si'an Fang1, Junbo Zhang1.   

Abstract

A novel glucose derivative (CN7DG) possessing an isonitrile as a coordinating group was synthesized, and 99mTc-CN7DG, which was expected to be a powerful tumor imaging agent for SPECT, was prepared in a kit by the reaction of CN7DG with SnCl2·2H2O and 99mTcO4-. 99mTc-CN7DG exhibited good stability and was transported via glucose transporters. Biodistribution results in mice bearing A549 tumor models showed that 99mTc-CN7DG had a higher uptake at the tumor sites and better tumor/blood and tumor/muscle ratios than did [18F]FDG and 99mTc-CN5DG. SPECT/CT imaging studies showed obvious accumulation in tumor sites, suggesting that 99mTc-CN7DG is a promising candidate for tumor imaging. Because 99mTc and 188Re stand for a "theranostic pair", 188Re-CN7DG is expected to be prepared as a promising agent for tumor therapy.

Entities:  

Keywords:  99mTc; cancer; glucose derivatives; imaging agents; isocyanide ligands

Year:  2021        PMID: 33586982     DOI: 10.1021/acs.molpharmaceut.0c01177

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  1 in total

1.  Phase I Clinical Trial Using [99mTc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients.

Authors:  Vladimir Chernov; Ekaterina Dudnikova; Roman Zelchan; Anna Medvedeva; Anstasiya Rybina; Olga Bragina; Viktor Goldberg; Albina Muravleva; Jens Sörensen; Vladimir Tolmachev
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.